2. Search Result
Search Result
Results for "

KMO

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

2

Natural
Products

1

Recombinant Proteins

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-119171
    GSK 366

    		KMO Neurological Disease Inflammation/Immunology
    GSK 366 is a type II kynurenine-3-monooxygenase (KMO) inhibitor with IC50 values of 2.3 nM and 0.7 nM for human KMO and P. fluorescens-KMO (Pf-KMO). GSK 366 binds to KMO’s substrate site, prevents productive NADPH association, substrate binding, and FAD hydroperoxy species formation. GSK 366 does not stimulate hydrogen peroxide (H2O2) production and reduces H2O2 levels. GSK 366 can be used for the researches of inflammation and neurological disease, such as acute pancreatitis multiple organ dysfunction syndrome and Alzheimer’s disease .
    GSK 366
  • HY-15600
    UPF-648
    1 Publications Verification

    		 Aryl Hydrocarbon Receptor Neurological Disease
    UPF-648 is a potent kynurenine 3-monooxygenase (KMO) inhibitor; exhibits highly active at 1 uM (81 ± 10% KMO inhibition); ineffective at blocking KAT activity.
    UPF-648
  • HY-112179
    GSK180
    2 Publications Verification

    		 KMO Inflammation/Immunology
    GSK180 is a selective, competitive, and potent inhibitor of kynurenine-3-monooxygenase (KMO), a key enzyme of tryptophan metabolism (IC50, ~6 nM), but shows negligible activity against other enzymes on the tryptophan pathway. GSK180 rapidly changes levels of kynurenine pathway metabolites, and acts as a useful tool to probe the therapeutic potential of KMO inhibition .
    GSK180
  • HY-W748591
    Cannflavin A

    		Apoptosis Amyloid-β KMO Neurological Disease Inflammation/Immunology Cancer
    Cannflavin A can be isolated from Cannabis sativa L.. Cannflavin A has anti-cancer, neuroprotective and anti-inflammatory activity. Cannflavin A inhibits Aβ1-42 aggregation. Cannflavin A also inhibits kynurenine-3-monooxygenase (KMO) (IC50 = 29.4 μM). Cannflavin A activates apoptosis via caspase-3 cleavage. Cannflavin A exerts anti-inflammatory effects by inhibiting pro-inflammatory enzymes, including prostaglandin E2 and cytochrome c oxidases I and II in PC12 cell line .
    Cannflavin A
  • HY-15500
    JM6

    		KMO Neurological Disease
    JM6 is a weak kynurenine 3-monooxygenase (KMO) inhibitor with an IC50 of 19.85 μM for mouse KMO. JM6 can be used for Alzheimer's diseases research .
    JM6
  • HY-RS07400
    KMO Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    KMO Human Pre-designed siRNA Set A contains three designed siRNAs for KMO gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    KMO Human Pre-designed siRNA Set A
    KMO Human Pre-designed siRNA Set A
  • HY-182692
    KMO-IN-1

    		KMO Inflammation/Immunology
    KMO-IN-1 is a KMO inhibitor with a mean pIC50 of 8.5 against KMO. KMO-IN-1 can be used in the research of acute pancreatitis .
    KMO-IN-1
  • HY-W748591R
    Cannflavin A (Standard)

    		Amyloid-β Apoptosis Reference Standards KMO Neurological Disease Inflammation/Immunology Cancer
    Cannflavin A (Standard) is the analytical standard of Cannflavin A. This product is intended for research and analytical applications. Cannflavin A can be isolated from Cannabis sativa L.. Cannflavin A has anti-cancer, neuroprotective and anti-inflammatory activity. Cannflavin A inhibits Aβ1-42 aggregation. Cannflavin A also inhibits kynurenine-3-monooxygenase (KMO) (IC50 = 29.4 μM). Cannflavin A activates apoptosis via caspase-3 cleavage. Cannflavin A exerts anti-inflammatory effects by inhibiting pro-inflammatory enzymes, including prostaglandin E2 and cytochrome c oxidases I and II in PC12 cell line .
    Cannflavin A (Standard)
  • HY-15600B
    UPF-648 sodium salt

    		Aryl Hydrocarbon Receptor Neurological Disease
    UPF-648 sodium salt is an effective inhibitor of kynurenine 3-monooxygenase (KMO), achieving approximately 81% inhibition at a concentration of 1uM, with no inhibitory effect on kynurenine aminotransferase (KAT).
    UPF-648 sodium salt
  • HY-RS18737
    Kmo Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Kmo Mouse Pre-designed siRNA Set A contains three designed siRNAs for Kmo gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Kmo Mouse Pre-designed siRNA Set A
    Kmo Mouse Pre-designed siRNA Set A
  • HY-RS25224
    Kmo Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Kmo Rat Pre-designed siRNA Set A contains three designed siRNAs for Kmo gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Kmo Rat Pre-designed siRNA Set A
    Kmo Rat Pre-designed siRNA Set A
  • HY-181988
    DTB-acid

    		Caspase KMO GSK-3 Neurological Disease
    DTB-acid is a multi-target inhibitor that binds stably to Caspase-6, KMO and GSK-3β. DTB-acid is applicable to the research of Huntington's disease .
    DTB-acid
  • HY-182456
    CHDI-340246

    		KMO Neurological Disease
    CHDI-340246 is an orally active kynurenine monooxygenase (KMO) inhibitor. CHDI-340246 blocks KMO activity, alters the metabolic flux of the kynurenine pathway, inhibits the production of 3-hydroxykynurenine and quinolinic acid, elevates the levels of kynurenine and kynurenic acid, and restores electrophysiological abnormalities in transgenic mouse models of Huntington's disease. CHDI-340246 can be used in studies related to Huntington's disease .
    CHDI-340246

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: